19043 research outputs found
Sort by
InTouch Week of April 22, 2024
Get PDFErika Berman Rosenzweig, M.D., to Lead NYMC Department of Pediatrics Distinguished Speakers Will Deliver Remarks to the Graduating Class of 2024 D.P.T. Class of 2026 Celebrates the Start of Clinicals with the White Coat Ceremony Division of Physical Therapy Hosts 20th Annual Doctoral Project Presentation Day NYMC Graduates Reunite at the Alumni Neurology Reunion NYMC Students’ Altruism Shines with Woodfield Cottage Youth Initiative Faculty Spotlight: Rebecca A. McAteer Martin, M.D. \u2708, Shares her Mission in Healinghttps://touroscholar.touro.edu/in_touch/1324/thumbnail.jp
Dupilumab-Associated Head and Neck Dermatitis Shows a Pronounced Type 22 Immune Signature Mediated by Oligoclonally Expanded T Cells
No full textDupilumab, an IL4R-blocking antibody, has shown clinical efficacy for atopic dermatitis (AD) treatment. In addition to conjunctivitis/blepharitis, the de novo appearance of head/neck dermatitis is now recognized as a distinct side effect, occurring in up to 10% of patients. Histopathological features distinct from AD suggest a drug effect, but exact underlying mechanisms remain unknown. We profiled punch biopsies from dupilumab-associated head and neck dermatitis (DAHND) by using single-cell RNA sequencing and compared data with untreated AD and healthy control skin. We show that dupilumab treatment was accompanied by normalization of IL-4/IL-13 downstream activity markers such as CCL13, CCL17, CCL18 and CCL26. By contrast, we found strong increases in type 22-associated markers (IL22, AHR) especially in oligoclonally expanded T cells, accompanied by enhanced keratinocyte activation and IL-22 receptor upregulation. Taken together, we demonstrate that dupilumab effectively dampens conventional type 2 inflammation in DAHND lesions, with concomitant hyperactivation of IL22-associated responses
Type 2 Diabetes and Chronic Kidney Disease: An Opportunity for Pharmacists to Improve Outcomes
No full textProgram ACTIVE II: 6- and 12-Month Outcomes of a Treatment Approach for Major Depressive Disorder in Adults with Type 2 Diabetes
No full textGlobal Burden of 288 Causes of Death and Life Expectancy Decomposition in 204 Countries and Territories and 811 Subnational Locations, 1990–2021: A Systematic Analysis for the Global Burden of Disease Study 2021
No full text
